Iniciar sesión Regístrese gratis

Akari Therapeutics Plc Rentabilidad sobre recursos propios

¿Qué es el Rentabilidad sobre recursos propios de Akari Therapeutics Plc?

El Rentabilidad sobre recursos propios de Akari Therapeutics Plc es -365.06%

¿Cuál es la definición de Rentabilidad sobre recursos propios?



El rendimiento del capital es una medida de la rentabilidad de una empresa en relación con el valor contable del capital contable. Se calcula dividiendo los ingresos netos del año fiscal por el capital contable total.

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

Rentabilidad sobre recursos propios de compañías en Sector Health Care en NASDAQ en comparadas con Akari Therapeutics Plc

¿Qué hace Akari Therapeutics Plc?

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.

Empresas con rentabilidad sobre recursos propios similar a Akari Therapeutics Plc